Zhiyong Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhiyong Deng has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Jianhao Xu
3 shared publicationsLanfen Pan
3 shared publicationsChen Zhang
Department of Rheumatology and Immunology, Kunshan First People’s Hospital, Suzhou, China
2 shared publicationsFang Cao
Emergency Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu, China
2 shared publicationsFang Li
2 shared publications- Hua Wu
Department of Pathology, The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Soochow University, Suzhou, China
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 171
Molecular genetic analysis of a case report of undifferentiated pleomorphic sarcoma with rhabdomyosarcomatous differentiation: insights from whole-exome sequencing and literature review
Background: Undifferentiated pleomorphic sarcoma (UPS) is one of the most common high-grade soft tissue sarcomas in adults, accounting for approximately 20–25% of all soft tissue sarcomas. However, the subtype with rhabdomyosarcomatous differentiation is exceedingly rare (Case Description: A 47-year-old woman presented with a 10-day history of abdominal pain, nausea, and vomiting. Imaging revealed an ill-defined cystic-solid mass measuring approximately 80 mm × 64 mm posterior and to the right of the uterus, with indistinct margins from the uterus and adjacent bowel loops, right lower abdominal peritoneal thickening, and pelvic effusion. The patient underwent laparoscopic total hysterectomy with bilateral salpingo-oophorectomy. Histopathological examination showed a high-grade pleomorphic spindle cell neoplasm with scattered rhabdomyoblasts. Immunohistochemistry (IHC) demonstrated focal nuclear positivity for MyoD1 and myogenin, confirming rhabdomyosarcomatous differentiation; desmin was positive, and the Ki-67 proliferation index was approximately 40%. Whole-exome sequencing (WES) identified 5,778 somatic mutations, including seven somatic missense mutations in TP53, ALK, NCOR2, GNAS, GOPC, PLEC, and STIP1, with a moderate tumor mutational burden (TMB) of 9.13 mutations/Mb. Conclusions: This case expands the pathological and molecular spectrum of UPS with rhabdomyosarcomatous differentiation. Increased clinical awareness, thorough immunohistochemical evaluation, and molecular profiling are essential to avoid misdiagnosis and to guide the management of this rare, aggressive sarcoma.
- 1 September 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 171
Open AccessMolecular genetic analysis of a case report of undifferentiated pleomorphic sarcoma with rhabdomyosarcomatous differentiation: insights from whole-exome sequencing and literature review
Background: Undifferentiated pleomorphic sarcoma (UPS) is one of the most common high-grade soft tissue sarcomas in adults, accounting for approximately 20–25% of all soft tissue sarcomas. However, the subtype with rhabdomyosarcomatous differentiation is exceedingly rare (Case Description: A 47-year-old woman presented with a 10-day history of abdominal pain, nausea, and vomiting. Imaging revealed an ill-defined cystic-solid mass measuring approximately 80 mm × 64 mm posterior and to the right of the uterus, with indistinct margins from the uterus and adjacent bowel loops, right lower abdominal peritoneal thickening, and pelvic effusion. The patient underwent laparoscopic total hysterectomy with bilateral salpingo-oophorectomy. Histopathological examination showed a high-grade pleomorphic spindle cell neoplasm with scattered rhabdomyoblasts. Immunohistochemistry (IHC) demonstrated focal nuclear positivity for MyoD1 and myogenin, confirming rhabdomyosarcomatous differentiation; desmin was positive, and the Ki-67 proliferation index was approximately 40%. Whole-exome sequencing (WES) identified 5,778 somatic mutations, including seven somatic missense mutations in TP53, ALK, NCOR2, GNAS, GOPC, PLEC, and STIP1, with a moderate tumor mutational burden (TMB) of 9.13 mutations/Mb. Conclusions: This case expands the pathological and molecular spectrum of UPS with rhabdomyosarcomatous differentiation. Increased clinical awareness, thorough immunohistochemical evaluation, and molecular profiling are essential to avoid misdiagnosis and to guide the management of this rare, aggressive sarcoma.
- Open Access
- 7 November 2025
- Published by Springer Nature in BMC Immunology
- Vol. 26 (1) , 1-11
Identification of gene modules associated with B cell activation and tissue remodeling in primary Sjögren’s syndrome
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune exocrinopathy affecting salivary and lacrimal glands. This study presents an exploratory single-cell transcriptomic analysis of labial salivary glands to generate hypotheses about B-cell–associated gene modules in pSS, and to uncover novel therapeutic targets for B cell modulation in pSS. The high-dimensional weighted gene co-expression network analysis (hdWGCNA) was performed on gene expression data obtained from single-cell RNA sequencing (scRNA-seq) of 32,337 cells from labial glands of three pSS patients and three healthy controls. Gene Ontology (GO) enrichment analysis was subsequently conducted to investigate the functional roles of the identified gene modules. Additionally, the scRank method was applied to evaluate the responsiveness of key B cell-related targets across different cell types, providing new insights into the role of B cells in the pathogenesis of pSS. Through hdWGCNA analysis, we resolved seven co-expression modules in pSS. Module 5, restricted to plasma cells, contains POU2AF1, SLAMF7, SPCS2, CD79A and PDIA6 and is highly enriched for COPI/II-mediated vesicle trafficking and B-cell-receptor signaling, thereby driving autoantibody production and chronic inflammation. Modules 1, 2, 4, 6 and 7 align with extracellular-matrix remodeling, epithelial stress and metabolic reprogramming, underscoring the disease’s multifactorial pathobiology. scRank ranked Module 5 as the most drug-responsive cluster and highlighted POU2AF1, SLAMF7 and CD79A as tractable B-cell targets for restoring immune homeostasis in pSS. Our study identified distinct gene modules associated with pSS, with a particular emphasis on B cells, unveiling novel potential therapeutic targets. The activation of B cells, coupled with immune dysregulation and epithelial dysfunction, appears to play a critical role in pSS pathogenesis, offering valuable insights for developing targeted therapeutic strategies that address both immune activation and tissue repair. These findings nominate B-cell–associated modules—including a plasma cell–enriched module featuring POU2AF1, SLAMF7, and CD79A—as hypotheses for future functional validation.
- 7 November 2025
- Published by Springer Nature in BMC Immunology
- Vol. 26 (1) , 1-11
Open AccessIdentification of gene modules associated with B cell activation and tissue remodeling in primary Sjögren’s syndrome
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune exocrinopathy affecting salivary and lacrimal glands. This study presents an exploratory single-cell transcriptomic analysis of labial salivary glands to generate hypotheses about B-cell–associated gene modules in pSS, and to uncover novel therapeutic targets for B cell modulation in pSS. The high-dimensional weighted gene co-expression network analysis (hdWGCNA) was performed on gene expression data obtained from single-cell RNA sequencing (scRNA-seq) of 32,337 cells from labial glands of three pSS patients and three healthy controls. Gene Ontology (GO) enrichment analysis was subsequently conducted to investigate the functional roles of the identified gene modules. Additionally, the scRank method was applied to evaluate the responsiveness of key B cell-related targets across different cell types, providing new insights into the role of B cells in the pathogenesis of pSS. Through hdWGCNA analysis, we resolved seven co-expression modules in pSS. Module 5, restricted to plasma cells, contains POU2AF1, SLAMF7, SPCS2, CD79A and PDIA6 and is highly enriched for COPI/II-mediated vesicle trafficking and B-cell-receptor signaling, thereby driving autoantibody production and chronic inflammation. Modules 1, 2, 4, 6 and 7 align with extracellular-matrix remodeling, epithelial stress and metabolic reprogramming, underscoring the disease’s multifactorial pathobiology. scRank ranked Module 5 as the most drug-responsive cluster and highlighted POU2AF1, SLAMF7 and CD79A as tractable B-cell targets for restoring immune homeostasis in pSS. Our study identified distinct gene modules associated with pSS, with a particular emphasis on B cells, unveiling novel potential therapeutic targets. The activation of B cells, coupled with immune dysregulation and epithelial dysfunction, appears to play a critical role in pSS pathogenesis, offering valuable insights for developing targeted therapeutic strategies that address both immune activation and tissue repair. These findings nominate B-cell–associated modules—including a plasma cell–enriched module featuring POU2AF1, SLAMF7, and CD79A—as hypotheses for future functional validation.
- Open Access
- 3 April 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-13
5-Methylcytosine RNA modification and its roles in cancer and cancer chemotherapy resistance
Recent advancements in cancer therapies have improved clinical outcomes, yet therapeutic resistance remains a significant challenge because of its complex mechanisms. Among epigenetic factors, m5C RNA modification is emerging as a key player in cancer drug resistance, similar to the well-known m6A modification. m5C affects RNA metabolism processes, including splicing, export, translation, and stability, thereby influencing drug efficacy. This review highlights the critical roles of m5C in modulating resistance to chemotherapy, targeted therapy, radiotherapy, and immunotherapy. This review also discusses the functions of key regulators, including methyltransferases, demethylases, and m5C-binding proteins, as essential modulators of the m5C epigenetic landscape that contribute to its dynamic and complex regulatory network. Targeting these regulatory components offers a promising strategy to overcome resistance. We highlight the need for further research to elucidate the specific mechanisms by which m5C contributes to resistance and to develop precise m5C-targeted therapies, presenting m5C-focused strategies as potential novel anticancer treatments.
- 3 April 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-13
Open Access5-Methylcytosine RNA modification and its roles in cancer and cancer chemotherapy resistance
Recent advancements in cancer therapies have improved clinical outcomes, yet therapeutic resistance remains a significant challenge because of its complex mechanisms. Among epigenetic factors, m5C RNA modification is emerging as a key player in cancer drug resistance, similar to the well-known m6A modification. m5C affects RNA metabolism processes, including splicing, export, translation, and stability, thereby influencing drug efficacy. This review highlights the critical roles of m5C in modulating resistance to chemotherapy, targeted therapy, radiotherapy, and immunotherapy. This review also discusses the functions of key regulators, including methyltransferases, demethylases, and m5C-binding proteins, as essential modulators of the m5C epigenetic landscape that contribute to its dynamic and complex regulatory network. Targeting these regulatory components offers a promising strategy to overcome resistance. We highlight the need for further research to elucidate the specific mechanisms by which m5C contributes to resistance and to develop precise m5C-targeted therapies, presenting m5C-focused strategies as potential novel anticancer treatments.
- Open Access
- 30 March 2025
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 55, 102198
Molecular genetic profiling of a rare case of primary pulmonary adenoid cystic carcinoma: Insights from whole exome sequencing and literature review
- 30 March 2025
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 55, 102198
Open AccessMolecular genetic profiling of a rare case of primary pulmonary adenoid cystic carcinoma: Insights from whole exome sequencing and literature review
- Open Access
- 24 December 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-16
Mitochondrial transcription elongation factor TEFM promotes malignant progression of gliomas
Gliomas are the most common tumors of the central nervous system, with glioblastoma (GBM) being particularly aggressive and fatal. Current treatments for GBM, including surgery and chemotherapy, are limited by tumor aggressiveness and the blood-brain barrier. Therefore, understanding the molecular mechanisms driving GBM growth is essential. Mitochondria, key players in cellular energy production, have been implicated in cancer development. In this study, we investigated the expression of mitochondrial transcription elongation factor (TEFM) in gliomas and its potential role in tumor progression. Analysis of data from The Cancer Genome Atlas (TCGA) revealed that TEFM transcript levels were significantly higher in glioma tissues compared to adjacent normal tissues. High TEFM expression was associated with poor survival outcomes in glioma patients. Furthermore, TEFM was notably upregulated in glioma tissue and in primary glioma cells derived from local patients, while its expression was relatively low in normal tissues and astrocytes. Silencing or knockout of TEFM significantly inhibited glioma cell growth, proliferation, clonogenicity, migration, and invasion, while inducing apoptosis and activating caspases. In contrast, ectopic overexpression of TEFM promoted tumorigenic activity, enhancing the malignant behavior of glioma cells. Co-expression analysis identified a strong correlation between TEFM and the epithelial-mesenchymal transition (EMT) pathway in gliomas. Notably, the expression of EMT markers, such as N-cadherin and Vimentin, decreased upon TEFM knockdown or knockout. Additionally, TEFM depletion impaired mitochondrial function, disrupting the mitochondrial respiratory chain in glioma cells. In vivo experiments demonstrated that TEFM knockout effectively suppressed the growth of subcutaneous glioma xenografts in nude mice. Collectively, these findings highlight the critical role of TEFM in GBM growth and invasion, suggesting that it could serve as a promising therapeutic target for glioma treatment.
- 24 December 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-16
Open AccessMitochondrial transcription elongation factor TEFM promotes malignant progression of gliomas
Gliomas are the most common tumors of the central nervous system, with glioblastoma (GBM) being particularly aggressive and fatal. Current treatments for GBM, including surgery and chemotherapy, are limited by tumor aggressiveness and the blood-brain barrier. Therefore, understanding the molecular mechanisms driving GBM growth is essential. Mitochondria, key players in cellular energy production, have been implicated in cancer development. In this study, we investigated the expression of mitochondrial transcription elongation factor (TEFM) in gliomas and its potential role in tumor progression. Analysis of data from The Cancer Genome Atlas (TCGA) revealed that TEFM transcript levels were significantly higher in glioma tissues compared to adjacent normal tissues. High TEFM expression was associated with poor survival outcomes in glioma patients. Furthermore, TEFM was notably upregulated in glioma tissue and in primary glioma cells derived from local patients, while its expression was relatively low in normal tissues and astrocytes. Silencing or knockout of TEFM significantly inhibited glioma cell growth, proliferation, clonogenicity, migration, and invasion, while inducing apoptosis and activating caspases. In contrast, ectopic overexpression of TEFM promoted tumorigenic activity, enhancing the malignant behavior of glioma cells. Co-expression analysis identified a strong correlation between TEFM and the epithelial-mesenchymal transition (EMT) pathway in gliomas. Notably, the expression of EMT markers, such as N-cadherin and Vimentin, decreased upon TEFM knockdown or knockout. Additionally, TEFM depletion impaired mitochondrial function, disrupting the mitochondrial respiratory chain in glioma cells. In vivo experiments demonstrated that TEFM knockout effectively suppressed the growth of subcutaneous glioma xenografts in nude mice. Collectively, these findings highlight the critical role of TEFM in GBM growth and invasion, suggesting that it could serve as a promising therapeutic target for glioma treatment.
- Open Access
- 16 July 2024
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 9, 100248
Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sjögren's syndrome
- 16 July 2024
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 9, 100248
Open AccessSingle-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sjögren's syndrome
- Open Access
- 26 June 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-15
Comparison of the diagnostic value of various microRNAs in blood for colorectal cancer: a systematic review and network meta-analysis
Background: Despite the existence of numerous studies investigating the diagnostic potential of blood microRNAs for colorectal cancer, the microRNAs under consideration vary widely, and comparative analysis of their diagnostic value is lacking. Consequently, this systematic review aims to identify the most effective microRNA blood tumor markers to enhance clinical decision-making in colorectal cancer screening. Method: A comprehensive search of databases, including PubMed, Embase, Web of Science, Scopus, and Cochrane, was conducted to identify case‒control or cohort studies that examined the diagnostic value of peripheral blood microRNAs in colorectal cancer. Studies were included if they provided sensitivity and specificity data, were published in English and were available between January 1, 2000, and February 10, 2023. The Critical Appraisal Skills Programme (CASP) checklist was employed for quality assessment. A Bayesian network meta-analysis was performed to estimate combined risk ratios (RRs) and 95% confidence intervals (CIs), with results presented via rankograms. This study is registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY), 202,380,092. Results: From an initial pool of 2254 records, 79 met the inclusion criteria, encompassing a total of 90 microRNAs. The seven most frequently studied microRNAs (43 records) were selected for inclusion, all of which demonstrated moderate to high quality. miR-23, miR-92, and miR-21 exhibited the highest sensitivity and accuracy, outperforming traditional tumor markers CA19-9 and CEA in terms of RR values and 95% CI for both sensitivity and accuracy. With the exception of miR-17, no significant difference was observed between each microRNA and CA19-9 and CEA in terms of specificity. Conclusions: Among the most extensively researched blood microRNAs, miR-23, miR-92, and miR-21 demonstrated superior diagnostic value for colorectal cancer due to their exceptional sensitivity and accuracy. This systematic review and network meta-analysis may serve as a valuable reference for the clinical selection of microRNAs as tumor biomarkers.
- 26 June 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-15
Open AccessComparison of the diagnostic value of various microRNAs in blood for colorectal cancer: a systematic review and network meta-analysis
Background: Despite the existence of numerous studies investigating the diagnostic potential of blood microRNAs for colorectal cancer, the microRNAs under consideration vary widely, and comparative analysis of their diagnostic value is lacking. Consequently, this systematic review aims to identify the most effective microRNA blood tumor markers to enhance clinical decision-making in colorectal cancer screening. Method: A comprehensive search of databases, including PubMed, Embase, Web of Science, Scopus, and Cochrane, was conducted to identify case‒control or cohort studies that examined the diagnostic value of peripheral blood microRNAs in colorectal cancer. Studies were included if they provided sensitivity and specificity data, were published in English and were available between January 1, 2000, and February 10, 2023. The Critical Appraisal Skills Programme (CASP) checklist was employed for quality assessment. A Bayesian network meta-analysis was performed to estimate combined risk ratios (RRs) and 95% confidence intervals (CIs), with results presented via rankograms. This study is registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY), 202,380,092. Results: From an initial pool of 2254 records, 79 met the inclusion criteria, encompassing a total of 90 microRNAs. The seven most frequently studied microRNAs (43 records) were selected for inclusion, all of which demonstrated moderate to high quality. miR-23, miR-92, and miR-21 exhibited the highest sensitivity and accuracy, outperforming traditional tumor markers CA19-9 and CEA in terms of RR values and 95% CI for both sensitivity and accuracy. With the exception of miR-17, no significant difference was observed between each microRNA and CA19-9 and CEA in terms of specificity. Conclusions: Among the most extensively researched blood microRNAs, miR-23, miR-92, and miR-21 demonstrated superior diagnostic value for colorectal cancer due to their exceptional sensitivity and accuracy. This systematic review and network meta-analysis may serve as a valuable reference for the clinical selection of microRNAs as tumor biomarkers.
- 24 June 2023
- Published by Elsevier in Cell Chemical Biology
- Vol. 30 (7) , 709-725.e6
TRIM21 is a druggable target for the treatment of metastatic colorectal cancer through ubiquitination and activation of MST2
- 24 June 2023
- Published by Elsevier in Cell Chemical Biology
- Vol. 30 (7) , 709-725.e6
TRIM21 is a druggable target for the treatment of metastatic colorectal cancer through ubiquitination and activation of MST2
- Open Access
- 8 September 2022
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 1010724
Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy
Immunotherapy has demonstrated great clinical success in the field of oncology in comparison with conventional cancer therapy. However, cancer immunotherapy still encounters major challenges that limit its efficacy against different types of cancers and the patients show minimal immune response to the immunotherapy. To overcome these limitations, combinatorial approaches with other therapeutics have been applied in the clinic. Simultaneously, nano-drug delivery system has played an important role in increasing the antitumor efficacy of various treatments and has been increasingly utilized for synergistic immunotherapy to further enhance the immunogenicity of the tumors. Specifically, they can promote the infiltration of immune cells within the tumors and create an environment that is more sensitive to immunotherapy, particularly in solid tumors, by accelerating tumor accumulation and permeability. Herein, this progress report provides a brief overview of the development of nano-drug delivery systems, classification of combinatory cancer immunotherapy and recent progress in tumor immune synergistic therapy in the application of nano-drug delivery systems.
- 8 September 2022
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 1010724
Open AccessRecent advances in nano-drug delivery systems for synergistic antitumor immunotherapy
Immunotherapy has demonstrated great clinical success in the field of oncology in comparison with conventional cancer therapy. However, cancer immunotherapy still encounters major challenges that limit its efficacy against different types of cancers and the patients show minimal immune response to the immunotherapy. To overcome these limitations, combinatorial approaches with other therapeutics have been applied in the clinic. Simultaneously, nano-drug delivery system has played an important role in increasing the antitumor efficacy of various treatments and has been increasingly utilized for synergistic immunotherapy to further enhance the immunogenicity of the tumors. Specifically, they can promote the infiltration of immune cells within the tumors and create an environment that is more sensitive to immunotherapy, particularly in solid tumors, by accelerating tumor accumulation and permeability. Herein, this progress report provides a brief overview of the development of nano-drug delivery systems, classification of combinatory cancer immunotherapy and recent progress in tumor immune synergistic therapy in the application of nano-drug delivery systems.
- Open Access
- 4 January 2022
- Published by Springer Nature in Journal of Inflammation
- Vol. 19 (1) , 1-8
TRIP6 promotes inflammatory damage via the activation of TRAF6 signaling in a murine model of DSS-induced colitis
Background: TRIP6 is a zyxin family member that serves as an adaptor protein to regulate diverse biological processes. In prior reports, TRIP6 was shown to play a role in regulating inflammation. However, its in vivo roles and mechanistic importance in colitis remain largely elusive. Herein, we therefore employed TRIP6-deficient (TRIP6−/−) mice in order to explore the mechanistic importance of TRIP6 in a dextran sodium sulfate (DSS)-induced model of murine colitis. Findings: Wild-type (TRIP6+/+) mice developed more severe colitis following DSS-mediated disease induction relative to TRIP6−/− mice, as evidenced by more severe colonic inflammation and associated crypt damage. TRIP6 expression in wild-type mice was significantly elevated following DSS treatment. Mechanistically, TRIP6 binds to TRAF6 and enhances oligomerization and autoubiquitination of TRAF6. This leads to the activation of NF-κB signaling and the expression of pro-inflammatory cytokines such as TNFα and IL-6, in the in vivo mouse model of colitis. Conclusions: These in vivo data demonstrate that TRIP6 serves as a positive regulator of DSS-induced colitis through interactions with TRAF6 resulting in the activation of inflammatory TRAF6 signaling, highlighting its therapeutic promise as a protein that theoretically can be targeted to prevent or treat colitis.
- 4 January 2022
- Published by Springer Nature in Journal of Inflammation
- Vol. 19 (1) , 1-8
Open AccessTRIP6 promotes inflammatory damage via the activation of TRAF6 signaling in a murine model of DSS-induced colitis
Background: TRIP6 is a zyxin family member that serves as an adaptor protein to regulate diverse biological processes. In prior reports, TRIP6 was shown to play a role in regulating inflammation. However, its in vivo roles and mechanistic importance in colitis remain largely elusive. Herein, we therefore employed TRIP6-deficient (TRIP6−/−) mice in order to explore the mechanistic importance of TRIP6 in a dextran sodium sulfate (DSS)-induced model of murine colitis. Findings: Wild-type (TRIP6+/+) mice developed more severe colitis following DSS-mediated disease induction relative to TRIP6−/− mice, as evidenced by more severe colonic inflammation and associated crypt damage. TRIP6 expression in wild-type mice was significantly elevated following DSS treatment. Mechanistically, TRIP6 binds to TRAF6 and enhances oligomerization and autoubiquitination of TRAF6. This leads to the activation of NF-κB signaling and the expression of pro-inflammatory cytokines such as TNFα and IL-6, in the in vivo mouse model of colitis. Conclusions: These in vivo data demonstrate that TRIP6 serves as a positive regulator of DSS-induced colitis through interactions with TRAF6 resulting in the activation of inflammatory TRAF6 signaling, highlighting its therapeutic promise as a protein that theoretically can be targeted to prevent or treat colitis.